1.Almeida LNB, et al. Cytomegalovirus seroepidemiology in an urban community of São Paulo, Brazil. Revista de Saude Publica 2001; 35: 124–129.
2.Fang FQ, et al. Incidence of cytomegalovirus infection in Shanghai, China. Clinical and Vaccine Immunology 2009; 16: 1700–1703.
3.Coonrod D, et al. Association between cytomegalovirus seroconversion and upper genital tract infection among women attending a sexually transmitted disease clinic: a prospective study. Journal of Infectious Diseases 1998; 177: 1188–1193.
4.Plotkin SA. Congenital cytomegalovirus infection and its prevention. Clinical Infectious Diseases 2004; 38: 1038–1039.
5.Porath A, et al. Effectiveness and cost benefit of a proposed live cytomegalovirus vaccine in the prevention of congenital disease. Reviews of Infectious Diseases 1990; 12: 31–40.
6.Pass RF, et al. Vaccine prevention of maternal cytomegalovirus infection. New England Journal of Medicine 2009; 360: 1191–1199.
7.Griffiths PD, McLean A, Emery VC. Encouraging prospects for immunisation against primary cytomegalovirus infection. Vaccine 2001; 19: 1356–1362.
8.Amaku M, et al. Vaccination against rubella: Analysis of the temporal evolution of the agedependent force of infection and the effects of different contact patterns. Physical Reviews E 2003; 67: 051907.
9.Amaku M, Azevedo RS. Estimating the true incidence of rubella. Mathematical Population Studies 2010; 17: 91–100.
10.Fernandes GCVR, et al. Seroepidemiology of Toxoplasma infection in a metropolitan region of Brazil. Epidemiology and Infection 2009; 137: 1809–1815.
11.Plotkin SA. Cytomegalovirus vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. Philadelphia: Saunders Elsevier, 2008, pp. 1147–1154.
12.Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine-live. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. Philadelphia: Saunders Elsevier, 2008, pp. 631–685.
13.Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Reviews in Medical Virology 2007; 17: 253–276.
15.Farrington CP. Modelling forces of infection for measles, mumps and rubella. Statistics in Medicine 1990; 9: 953–967.
16.Lübeck PR, Doerr HW, Rabenau HF. Epidemiology of human cytomegalovirus (HCMV) in an urban region of Germany: what has changed? Medical Microbiology and Immunology 2010; 199: 53–60.
17.Cui X, et al. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 2008; 26: 5760–5766.
18.Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. Journal of the American Medical Association 2003; 289: 1008–1011.
19.Yamamoto AY, et al. Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirus-immune maternal population. American Journal of Obstetrics and Gynecology 2010; 202: 297.e1–8.